NanoLive

Executive Summary

NanoLive, a Swiss biotech founded in 2013, revolutionizes live cell imaging with its label-free holotomography technology. By combining high-resolution 3D imaging with AI-driven digital assays, the company enables non-invasive, quantitative analysis of living cells and organelles, eliminating the need for dyes or labels. This approach accelerates drug discovery and cell biology research by providing real-time, dynamic cellular insights. NanoLive's platform addresses critical bottlenecks in preclinical development, offering researchers a powerful tool to observe cellular processes without perturbation. With its innovative hardware-software integration, the company is poised to disrupt the traditional microscopy market, capturing value in both diagnostics and drug delivery applications. The company's pre-clinical stage suggests potential for near-term validation and partnerships.

Upcoming Catalysts (preview)

• Q3 2026Launch of Next-Generation Holotomography System with Enhanced AI Analytics70% success
• Q4 2026Strategic Partnership with Major Pharma for Drug Discovery Applications50% success
• Q2 2026Series A Funding Round to Scale Commercial Operations80% success